Salve accelerates gene therapy development by employing computational tools to generate virtual prototypes of drug candidates. This platform enables small and medium-sized biotech firms to optimize the precision of their viral-based gene therapies while reducing R&D timelines and associated costs. The service focuses on delivering smarter discovery processes to improve therapeutic safety and efficiency.
Funding
Funding not disclosed
Founders
Product
Problem
Developing novel viral therapeutics for cell and gene therapies, vaccines, and antibiotics is inefficient due to the complexity of viral design and the limitations of traditional modeling and testing methods. Current approaches lack the precision needed to create targeted therapies, hindering the development of effective treatments for genetic diseases.
Solution
VirCAD is a cloud-accessible, computer-aided design (CAD) platform that leverages high-performance computing and AI/ML to streamline the design, modeling, and testing of viral therapeutics. The platform enables biopharma researchers to mine and analyze the human virome, facilitating the discovery of novel therapeutic candidates. By improving viral delivery methods, VirCAD supports the development of precision medicines for genetic diseases and other conditions.
Target Audience
The primary target audience includes biopharmaceutical researchers and companies involved in cell and gene therapy, vaccine development, and antibiotic research.
Features
- Cloud-based platform accessible via web browser
- High-performance computing infrastructure for rapid simulations
- AI/ML algorithms for predictive modeling of viral behavior
- CAD-style interface for intuitive design and manipulation of viral vectors
- Integrated tools for mining and analyzing virome data